GLP-S, in brief. GLP-1 is a hormone released from cells in the gut wall after food arrives, and its job is to tell the pancreas to release insulin, but only while glucose is high. Native GLP-1 is cut apart within minutes by an enzyme called DPP-4, which makes the natural hormone almost useless as a laboratory tool. GLP-S is a 31-residue rebuild of that hormone designed to last. One substituted amino acid at position 8 blocks the enzyme, and a long fatty acid chain hung off position 26 makes the molecule cling to albumin, the main carrier protein in blood, so it is released slowly instead of being cleared. The result is a GLP-1 receptor agonist that keeps the receptor engaged for days rather than minutes, with a half-maximal response of 6.2 pM in cell assays. In diet-induced obese mice it cut food intake and lowered body weight over three weeks, and in two strains of mice bred to build arterial plaque it slowed plaque development and reversed much of the inflammatory gene signature that goes with it. NextGenPeps supplies GLP-S as a 10 mg lyophilised research material for laboratory use only.
What does GLP-S do?
It switches on one receptor, the GLP-1 receptor, and holds it switched on far longer than the natural hormone can. Everything further down this page follows from those two facts: which receptor, and for how long.
In practice that means three things:
At the receptor, it is a full agonist at the GLP-1 receptor, a class B G-protein-coupled receptor, with a half-maximal response of 6.2 pM in cell assays against 8.5 pM for liraglutide measured alongside it.[1]
In circulation, it binds albumin strongly. Adding 2% albumin to the assay shifted its receptor IC50 by a factor of 940, against 43 for liraglutide, and its intravenous half-life in Goettingen minipigs was 46.1 hours against 12.4 hours.[1]
In animals, it lowered food intake and body weight in diet-induced obese mice[2] and slowed plaque development in two atherosclerosis-prone mouse strains.[3]
NextGenPeps supplies GLP-S for in vitro research and approved animal studies only. It is not sold as a drug, supplement, diagnostic or food.
How does GLP-S work?
Through the GLP-1 receptor, and then through whatever tissue that receptor happens to sit in.
The route from binding to effect is short. The GLP-1 receptor is a class B G-protein-coupled receptor. When an agonist binds, the receptor activates the G protein Gs, the cell raises its level of the messenger molecule cAMP, and cAMP activates protein kinase A. In pancreatic beta cells that output is glucose-dependent insulin secretion, which stops when glucose falls. The same receptor is expressed well beyond the pancreas, and GLP-1 signalling has been linked to slowed gastric emptying, reduced food intake, natriuresis and diuresis, and beta-cell proliferation in rodents.[4]
What GLP-S changes is duration, not the pathway. Two modifications do the work. Aib, an unnatural amino acid, replaces alanine at position 8, the site DPP-4 cleaves, so the enzyme cannot cut the peptide. A C-18 fatty diacid attached at position 26 binds albumin, which both shields the molecule from clearance and releases it slowly back into circulation.[1]
Where the signal reaches in the brain has been mapped directly. In mice, a labelled version of the compound did not cross the blood-brain barrier. It reached the area postrema, the nucleus tractus solitarius and the dorsal motor nucleus of the vagus, sites served by circumventricular organs and sites adjacent to the ventricles, and from there activated a wider set of nuclei. Mapping the immediate-early gene c-Fos found activation in ten nuclei in all, including the bed nucleus of the stria terminalis, the central amygdala, the parabrachial nucleus and the parasubthalamic nucleus, most of it secondary rather than direct.[2]

Figure 1. How GLP-S signals.
GLP-S binds albumin through its C-18 diacid side chain, which slows clearance, and activates the GLP-1 receptor through Gs, cAMP and protein kinase A. Downstream readouts shown are glucose-dependent insulin release from islets, access to brainstem and hypothalamic nuclei via circumventricular organs, lower food intake and body weight in rodents, and reduced plaque with lower inflammatory gene expression in the arterial wall of mice.[1,2,3] Simplified.
What did GLP-S do in animal studies?
It made obese mice eat less and weigh markedly less within three weeks, and it slowed plaque formation in mice bred to build it.
The clearest body weight data come from diet-induced obese mice treated twice daily for three weeks, nine animals per group. At the lowest dose tested, mean body weight fell from 42.5 g to 38.2 g, a loss of 4.3 g. At the highest dose tested it fell from 43.6 g to 34.8 g, a loss of 8.8 g, which the authors describe as a 22% reduction from baseline. Food intake suppression was front-loaded: it was maximal within the first five days and on day 1 at the highest dose intake ran 68.2% (plus or minus 4.3%) below vehicle, then faded. Fat mass fell; the change in lean mass was minor and not significant against vehicle.[2]

Figure 2. GLP-S lowered body weight in diet-induced obese mice.
Mean body weight at baseline and after three weeks of twice-daily treatment, nine animals per group. The highest dose tested produced an 8.8 g fall, described in the paper as a 22% reduction from baseline, and day-1 food intake at that dose ran 68.2% below vehicle. Source: Gabery et al. 2020, JCI Insight 5(6):e133429.[2]
A separate 11-day calorimetry experiment asked whether the weight loss was simply a slowed metabolism, and found that it was not. At a dose producing a 17% to 18% reduction in body weight, food-restricted controls matched for weight showed a sustained fall in energy expenditure in both the dark and light phases. GLP-S reduced dark-phase energy expenditure only until day 6, after which it was no longer significantly lower than vehicle, and after adjusting for lean mass there was no difference from vehicle at all.[2]
In the arterial wall, two atherosclerosis-prone mouse strains were studied: mice lacking apolipoprotein E and mice lacking the LDL receptor, fed a Western diet. GLP-S and liraglutide both reduced plaque development, and the effect was partly independent of the change in weight and in cholesterol. The Western diet shifted aortic gene expression in pathways tied to leukocyte recruitment and adhesion, cholesterol metabolism and plaque haemorrhage, and GLP-S reversed many of those shifts, which is what led the authors to an inflammatory mechanism. The published abstract gives no plaque area percentages, so none are quoted here.[3]
GLP-S vs GLP-TZ vs GLP-RT: which receptors each one targets
They differ in how many receptors they engage. This section compares receptor targets and compound class only, and makes no comparison of effectiveness.
GLP-S. Class: single-receptor acylated GLP-1 analogue. Receptor target: the GLP-1 receptor only.[1]
GLP-TZ. Class: dual incretin receptor agonist. Receptor targets: the GIP receptor and the GLP-1 receptor.[5]
GLP-RT. Class: triple agonist. Receptor targets: the GIP receptor, the GLP-1 receptor and the glucagon receptor.[6]
The three receptors belong to different hormones. GLP-1 and GIP are the two incretin hormones, both released from the gut wall after food arrives, and both raise insulin secretion in a glucose-dependent way. Glucagon is the pancreatic hormone that acts in the opposite direction on glucose and that also raises energy expenditure. Engaging more receptors engages more pathways, which is the stated design rationale for the dual and triple molecules.[5,6] GLP-S is the single-receptor member of the set and is often used as the reference point in preclinical pharmacology for exactly that reason.
What is GLP-S made of?
A 31-amino-acid peptide backbone with three deliberate changes written into it.
The backbone is GLP-1(7-37), the active form of the natural hormone. Three changes separate GLP-S from it. Aib, an unnatural amino acid, replaces alanine at position 8, which blocks DPP-4 cleavage. Arginine replaces lysine at position 34, which leaves a single lysine for the side chain to attach to. And a C-18 fatty diacid is attached to the lysine at position 26 through a linker made of one gamma-glutamate unit and two short ethylene glycol (OEG) spacers.[1]
Sequence: His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(C-18 diacid via gamma-Glu and two OEG units)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly
The molecular formula is C187H291N45O59, giving an average molecular weight of 4113.58 Da, a monoisotopic mass of 4111.12 Da and a heavy atom count of 291. The linker chemistry, not the fatty acid alone, is what the design turned on: the spacer length sets how far the albumin anchor sits from the peptide, and that distance has to balance albumin affinity against receptor potency, since a molecule bound tightly to albumin is not available to the receptor.[1]
What the crystal structure does and does not show. PDB 4ZGM resolves the GLP-S peptide backbone bound to the extracellular domain of the GLP-1 receptor at 1.8 angstrom. It is the unacylated backbone: the C-18 diacid side chain and its linker, the parts responsible for the long duration, are not in the model. The structure describes receptor recognition, not the albumin interaction.[1,7]

Figure 3. GLP-S in vitro: receptor potency and albumin binding.
Both measurements come from the same study, with liraglutide run alongside as the comparator. GLP-S reached a half-maximal response at 6.2 pM against 8.5 pM for liraglutide, while 2% albumin shifted its receptor IC50 by a factor of 940 against 43 for liraglutide. Source: Lau et al. 2015, J Med Chem 58:7370-7380. Cell assay values are not interchangeable with other assay systems.[1]
GLP-S at a glance
Compound: GLP-S, the NextGenPeps catalogue code for this acylated GLP-1 analogue
Class: Acylated GLP-1 receptor agonist; the receptor (GLP1R) is a class B G-protein-coupled receptor
Sequence: 31 residues on a GLP-1(7-37) backbone, with Aib at position 8, Arg at position 34 and a C-18 fatty diacid on Lys26 via gamma-Glu and two OEG spacers[1]
Molecular formula: C187H291N45O59
Molecular weight: 4113.58 Da average, 4111.12 Da monoisotopic, 291 heavy atoms
Strength per vial: 10 mg
Receptor potency: Half-maximal response at 6.2 pM in cell assays, against 8.5 pM for liraglutide measured alongside[1]
Albumin binding: 2% albumin shifted the receptor IC50 by a factor of 940, against 43 for liraglutide[1]
Half-life: 46.1 hours after intravenous dosing in Goettingen minipigs, against 12.4 hours for liraglutide[1]
Identity and purity: Every lot is tested by independent labs and the certificate of analysis is published in the NextGenPeps COA library
Appearance: White lyophilised powder, sealed vial
Reconstitution: Sterile or bacteriostatic water
Structure: PDB 4ZGM, peptide backbone bound to the receptor extracellular domain at 1.8 angstrom[1,7]
Regulatory status: Research use only. GLP-S is not an approved medicine and is not sold as a drug, supplement, diagnostic or food
Is GLP-S FDA approved?
No. GLP-S is a research material, not an approved medicine, and no regulatory authority has reviewed or authorised it for any use. It is supplied for in vitro work and approved animal studies only. Nothing on this page should be read as a claim that it has been approved for anything, or that it stands in for any product that has.
What is GLP-S used to study?
Researchers reach for GLP-S when they need the GLP-1 receptor held active for days in a model rather than minutes. Each of the fields below leans on a different property of the molecule.
Incretin receptor pharmacology. Potency, albumin binding and duration at the GLP-1 receptor, with GLP-S serving as a long-acting reference agonist in cell assays.[1]
Feeding and body composition in rodents. Diet-induced obese mouse models of food intake, body weight, fat and lean mass, and energy expenditure by indirect calorimetry.[2]
Central nervous system access. Which brain nuclei a peripherally delivered GLP-1 agonist reaches directly and which it activates indirectly, mapped by labelled compound and c-Fos.[2]
Atherosclerosis in mice. Plaque development and aortic inflammatory gene expression in apolipoprotein E deficient and LDL receptor deficient strains on a Western diet.[3]
Multi-receptor peptide design. GLP-S as the single-receptor comparator against dual and triple incretin receptor agonists in preclinical pharmacology.[5,6]
Buying GLP-S for research: what each vial includes
Each vial holds 10 mg of GLP-S as a sealed lyophilised powder. For an acylated peptide, identity matters as much as a purity percentage, because the albumin binding and the long duration both depend on an intact fatty acid side chain that a purity number alone will not report on.
Independent lot testing. Every lot is tested by independent labs and the certificate of analysis is published in the NextGenPeps COA library.
US-based fulfilment. Orders ship within 24 hours from the United States, with free US shipping on orders over $150.
Research use only. GLP-S is sold strictly for in vitro and approved animal research. It is not for human or veterinary use and is not sold as a drug, supplement, diagnostic or food.
GLP-S handling, storage and analytical notes
Format. Supplied as 10 mg of lyophilised powder in a sealed vial and reconstituted with sterile or bacteriostatic water. No dosing instructions are supplied, and none should be taken from the studies described above.
Storage. Keep the sealed vial cold, at 2 to 8 degrees Celsius, or at minus 20 degrees Celsius for longer holding, protected from light and moisture. After reconstitution, hold the solution at 2 to 8 degrees Celsius and avoid repeated freeze-thaw cycles.
Adsorption. Acylated peptides are surface active and can adsorb to glass and plastic at low working concentrations, which shows up as apparent loss of potency. Low-binding labware and a carrier protein in the buffer reduce those losses.
Analysis. Mass spectrometry is the informative identity test here, because the intact mass reports whether the fatty acid side chain is present. RP-HPLC at 214 nm separates the acylated peptide from des-acyl and truncated species that a mass check alone may not flag.
Albumin in the assay. Receptor potency measured with albumin present is very different from potency measured without it: the shift reported above is a factor of 940. Any potency figure for this compound should state the albumin concentration in the assay buffer, or it cannot be compared with another laboratory's number.[1]
Naming. GLP-S is the NextGenPeps catalogue code for this compound. GLP-TZ and GLP-RT are separate catalogue codes for different molecules with different receptor targets, and results obtained with one do not transfer to the others.
What is not established about GLP-S
Transfer beyond the models studied. The body weight, feeding and plaque findings above come from particular mouse strains on particular diets over weeks. They do not transfer automatically to other species, other models or longer timescales.[2,3]
The mechanism behind the plaque effect. The atherosclerosis work reports an effect that is partly independent of weight and cholesterol change and points towards inflammatory pathways, but it does not establish which pathway is responsible.[3]
Which brain sites drive which outcome. Direct access was found at the area postrema, nucleus tractus solitarius and dorsal motor nucleus of the vagus, with activation elsewhere mostly secondary. Which of those nuclei account for the feeding and weight results is not resolved.[2]
Research-grade potency and stability. Research-grade peptide is not manufactured to pharmaceutical potency or sterility standards, and no stability dataset is supplied, so quantitative work should calibrate against its own reference material.
Research Use Only. The statements made within this website have not been evaluated by the US Food and Drug Administration. These materials are not intended to diagnose, treat, cure or prevent any disease and are not intended for human or veterinary use. Studies described on this page are reported for scientific context and are not guidance of any kind.